Pfizer (PFE) Terminates Domagrozumab Clinical Studies for the Treatment of DMD
August 30, 2018 8:00 AM
Pfizer Inc. (NYSE: PFE) announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)